For the first time, the recommendations factor in cost-effectiveness for vaccinating those at lower risk, partly due to concerns about maintaining coverage of crucial routine vaccines such as measles.
Order of the health officer requiring healthcare workers in designated health facilities to receive their influenza vaccine each year during influenza season. The deadline to complete the annual requirement is no later than October 31st.
New York State Education laws 6527, 6801, and 6909 permit licensed pharmacists, who obtain an additional certification, to administer influenza vaccine to children between the ages of 2 and 18 years of age and to adults 18 years of age and older, and to administer pneumococcal, meningococcal, tetanus, diphtheria, pertussis and herpes zoster vaccinations to adults 18 years of age and older under either patient specific or non-patient specific orders.
A non-patient specific order must be signed by a New York State licensed physician or nurse practitioner practicing in the same or adjoining county the pharmacist will be administering vaccine. Links to examples of non-patient specific standing orders are provided below. Before signing/practicing under any non-patient specific standing order, a review of such order, including any necessary modifications, should be completed to ensure compliance with New York State Education Law. Requirements for non-patient specific standing orders can be found in New York State Education Regulations at 8 NYCRR 63.9.
The CDC recommends that everyone six months of age and older get the flu vaccine every season. In addition to the flu vaccine for adults, teens, and children, there are flu vaccines approved for different groups:
The flu vaccine is especially important for people with chronic health conditions and those who have a high risk of developing complications from the flu. If you have questions about which vaccine is best for you, talk to your doctor or other healthcare professional.
*Subject to availability. Eligibilty criteria apply. Inejctable vaccine, 9.95 (or 21.99 in Jersey). Some areas provide a free flu vaccination programme in schools, which may include some secondary year groups.
The 2023-24 season will see further changes as MASTA will not be supplying flu vaccines to the GP market next year. This will leave only three providers: CSL Seqirus, Viatris (formerly Mylan) and Sanofi.
Our role in this upcoming flu season has been liaising with the providers to collate vaccine information and the terms offered by each provider such as sale or return, reserves, and early delivery. We are then able to share this information with our members, so you feel confident placing your orders, and knowing you have secured the delivery dates to suit your practice.
Yes. For example, the list reflects immunizations added in June and October 2001. Other vaccines can be added in the future and we will seek ways to expedite the process within the limits of public protection.
Yes. However, in the case of the adult influenza vaccine the following exception has been made: For the purpose of administering the influenza vaccine to adults only, it is acceptable to maintain a log of the names, addresses and phone numbers of all adult recipients immunized with the influenza vaccine under non-patient specific orders, in a dated file with a copy of the influenza order, the influenza protocol, and identification information of the immunizing agent attached to the log.
It is essential that those who immunize a large number of people make every effort to locate and notify a provider as part of a united effort to prevent over-immunization. For the administration of the influenza vaccine to adults only, acceptable practices include such examples as having a patient fill out a postcard that the nurse or agency can send to the primary care provider or having a patient sign a consent form on the certificate of immunization agreeing to provide the primary care provider with a copy of the certificate listing the immunization provided.
FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older. This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT.
AFLURIA QUADRIVALENT (Influenza Vaccine) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.
FLUCELVAX QUADRIVALENT (Influenza Vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 6 months of age and older.
Do not administer FLUAD QUADRIVALENT or AFLURIA QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine. Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine.
If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUAD QUADRIVALENT, AFLURIA QUADRIVALENT or FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT and FLUCELVAX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Ensure procedures are in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.
This brief explains how vaccines are covered and paid for through government programs and different types of insurance, including information on specific policies put into place for a COVID-19 vaccine. We describe vaccine coverage, patient cost sharing, and pricing in Medicare; private health insurance; the Vaccines for Children Program (VFC); Medicaid; Section 317 of the Public Health Services Act, which is the federal program that provides vaccines for uninsured adults; and the Department of Veterans Affairs (VA). Our brief also includes background information on how the CDC develops vaccine recommendations, since many of the federal vaccine coverage requirements currently in place are tied to those recommendations. The brief also includes three tables. Table 1 provides the price per regimen of vaccines that the U.S. government has already purchased. Table 2 summarizes how vaccine prices are set in each program or type of insurance, and Table 3 compares vaccine list prices with prices paid by Vaccines for Children program and Section 317, the Veterans Administration, as well as prices paid by Medicare Part B and Medicare Part D (not accounting for rebates).
Vaccines for influenza, pneumococcal disease, and hepatitis B (for patients at high or intermediate risk), and vaccines needed to treat an injury or exposure to disease are covered under Part B. All other commercially available vaccines needed to prevent illness are covered under Medicare Part D. Vaccine pricing, provider reimbursement, and patient out-of-pocket costs vary under both parts of Medicare. 59ce067264